论文部分内容阅读
目的比较经导管动脉化疗栓塞(TACE)联合经皮穿刺射频消融(PRFA)与单独TACE治疗原发性肝癌的临床疗效。方法利用计算机检索PubMed、MEDLINE、中国期刊全文数据库(CJFD)及万方数据库收录的有关比较TACE联合PRFA和单独TACE治疗原发性肝癌临床疗效的文献。按照Cochrane协作网推荐的方法,利用RevMan 4.2.2.软件进行Meta分析。结果 Meta分析结果显示,TACE序贯联合PRFA治疗原发性肝癌的1年、2年和3年生存率明显优越于单独TACE治疗(OR1年=3.70,95%CI 2.64~5.20,P<0.001;OR2年=3.34,95%CI2.37~4.70,P<0.001;OR3年=4.29,95%CI 2.31~7.97,P<0.001)。结论 TACE序贯联合PRFA治疗原发性肝癌,在改善患者预后和提高生存率方面明显优越于单独TACE治疗。
Objective To compare the clinical efficacy of transcatheter arterial chemoembolization (TACE) with percutaneous radiofrequency ablation (PRFA) and TACE alone in the treatment of primary liver cancer. Methods The clinical data of PubMed, MEDLINE, Chinese Journal Full-text Database (CJFD) and Wanfang database were compared by computer to compare the clinical efficacy of TACE with PRFA and TACE in the treatment of primary liver cancer. Meta-analysis was performed using RevMan 4.2.2 software in accordance with the methodology recommended by the Cochrane Collaboration. Results The results of Meta analysis showed that the 1-year, 2-year and 3-year survival rates of TACE combined with PRFA for primary hepatocellular carcinoma were significantly superior to those of TACE alone (OR1 = 3.70, 95% CI 2.64-5.20, P <0.001; OR2 = 3.34, 95% CI 2.37 ~ 4.70, P <0.001; OR3 = 4.29, 95% CI 2.31 ~ 7.97, P <0.001). Conclusions TACE sequential combined with PRFA in the treatment of primary liver cancer is significantly superior to TACE in improving prognosis and improving survival rate.